Aksys, Ltd.
Dialysis systems developer files registration statement with SEC
Published in Pharma Investments, Ventures and Law Weekly, May 16th, 2004
The selling security holders advised the company that, as of April 12, 2004, they have not determined the specific amount, price or timing of any sales of their securities and that they will determine any such sales using the registration statement in their sole discretion.
In compliance with standard registration procedures, the registration statement, once declared effective by the Securities and Exchange Commission, will cover future sales of shares of the company's common stock and warrants, as applicable, held...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Abiomed, Inc.
Option grant to new CEO reported under NASDAQ marketplace rule - Advanced Magnetics, Inc.
Nanobiotech company reports loss of $0.07 per share - Affymax, Inc.
Peptide drug maker completes Series C financing, adds new board member - Agentase, LLC
Biocatalyst maker receives $100,000 investment - AngioGenex, Inc.
Oncology company completes bridge financing - Avanir Pharmaceuticals
Pharmaceutical company files shelf registration statement - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
